An association of patients and their families, since its creation in 1958, the AFM-Telethon has the same objective: overcome the inevitable and cure rare genetic diseases that have long been neglected and ignored by all.
Thanks to the extraordinary popular support of the Telethon for the past 25 years and driven by the sole interest of patients, the AFM-Telethon has become a major player for the research and development of innovative therapies for rare diseases, thus contributing to the emergence of a genuine medical revolution that benefits all rare diseases and all persons with disabilities. Today, the AFM-Telethon supports 36 clinical trials involving thirty different diseases (rare diseases of the skin, muscle, eyesight, blood, liver,… myocardial infarction…).
At the end of 2011, the association grouped four laboratories that are leaders in the fields of gene therapy and cell therapy (Genethon, Institute of Myology, I-Stem, Atlantic Gene Therapies) into The Biotherapies Institute, which brings together 650 experts from research and development. Through its Genethon laboratory, it has also just opened the most important international centre for the production of gene therapy treatments to pharmaceutical standards (GMP) for clinical trials for rare diseases.
